Von Hoff DD - Search Results

1

New drugs for patients with pancreatic cancer.

Von Hoff DD, Bearss D. Von Hoff DD, et al. Curr Opin Oncol. 2002 Nov;14(6):621-7. doi: 10.1097/00001622-200211000-00006. Curr Opin Oncol. 2002. PMID: 12409652 Review.

2

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

Von Hoff DD, Goodwin AL, Garcia L. Von Hoff DD, et al. Br J Cancer. 1998;78 Suppl 3(Suppl 3):9-13. doi: 10.1038/bjc.1998.748. Br J Cancer. 1998. PMID: 9717985 Free PMC article. Review.

3

Telomere maintenance mechanisms as a target for drug development.

Bearss DJ, Hurley LH, Von Hoff DD. Bearss DJ, et al. Among authors: von hoff dd. Oncogene. 2000 Dec 27;19(56):6632-41. doi: 10.1038/sj.onc.1204092. Oncogene. 2000. PMID: 11426649 Review.

4

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

5

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. Grand CL, et al. Among authors: von hoff dd. Mol Cancer Ther. 2002 Jun;1(8):565-73. Mol Cancer Ther. 2002. PMID: 12479216

6

Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.

Vankayalapati H, Bearss DJ, Saldanha JW, Muñoz RM, Rojanala S, Von Hoff DD, Mahadevan D. Vankayalapati H, et al. Among authors: von hoff dd. Mol Cancer Ther. 2003 Mar;2(3):283-94. Mol Cancer Ther. 2003. PMID: 12657723

7

Targeting Aurora-2 kinase in cancer.

Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Among authors: von hoff dd. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.

8

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

9

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. Gray PJ Jr, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 May;3(5):641-6. Mol Cancer Ther. 2004. PMID: 15141022

10

Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.

Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD. Wadkins RM, et al. Among authors: von hoff dd. Curr Med Chem Anticancer Agents. 2004 Jul;4(4):327-34. doi: 10.2174/1568011043352894. Curr Med Chem Anticancer Agents. 2004. PMID: 15281905

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

773 results

Search Page

Filters